"Fluorouracil" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
| Descriptor ID |
D005472
|
| MeSH Number(s) |
D03.383.742.698.875.404
|
| Concept/Terms |
Fluorouracil- Fluorouracil
- 5FU
- 5-FU
- 5-Fluorouracil
- 5 Fluorouracil
- Fluoruracil
Efudix- Efudix
- Fluoro-Uracile ICN
- Fluoro Uracile ICN
- Efudex
|
Below are MeSH descriptors whose meaning is more general than "Fluorouracil".
Below are MeSH descriptors whose meaning is more specific than "Fluorouracil".
This graph shows the total number of publications written about "Fluorouracil" by people in this website by year, and whether "Fluorouracil" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 8 | 9 |
| 1997 | 1 | 4 | 5 |
| 1998 | 4 | 6 | 10 |
| 1999 | 3 | 6 | 9 |
| 2000 | 3 | 7 | 10 |
| 2001 | 4 | 6 | 10 |
| 2002 | 5 | 6 | 11 |
| 2003 | 3 | 5 | 8 |
| 2004 | 1 | 7 | 8 |
| 2005 | 1 | 8 | 9 |
| 2006 | 1 | 4 | 5 |
| 2007 | 0 | 5 | 5 |
| 2008 | 2 | 3 | 5 |
| 2009 | 5 | 3 | 8 |
| 2010 | 0 | 7 | 7 |
| 2011 | 0 | 10 | 10 |
| 2012 | 2 | 10 | 12 |
| 2013 | 2 | 6 | 8 |
| 2014 | 3 | 6 | 9 |
| 2015 | 2 | 3 | 5 |
| 2016 | 1 | 5 | 6 |
| 2017 | 1 | 5 | 6 |
| 2018 | 0 | 3 | 3 |
| 2019 | 2 | 3 | 5 |
| 2020 | 2 | 4 | 6 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 3 | 3 |
| 2023 | 1 | 5 | 6 |
| 2024 | 3 | 2 | 5 |
| 2025 | 1 | 3 | 4 |
| 2026 | 0 | 7 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fluorouracil" by people in Profiles.
-
Cancer treatment alters mutant selection in normal esophagus. Nat Genet. 2026 Oct; 58(10):2566-2578.
-
Addition of High-Dose Vitamin D3 to Standard Treatment in Patients With Metastatic Colorectal Cancer: The SOLARIS Randomized Clinical Trial (Alliance A021703). JAMA. 2026 Sep 01; 336(9):746-754.
-
ECOG-ACRIN E6293: Phase II Study of Raltitrexed in Advanced Colorectal Cancer. Oncologist. 2026 Apr 10; 31(5).
-
Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer. N Engl J Med. 2026 Mar 26; 394(12):1155-1166.
-
Consensus Molecular Subtypes Inform HIPEC Agent Selection in Colorectal Cancer Peritoneal Metastases. Ann Surg Oncol. 2026 Jul; 33(7):6140-6145.
-
Association of Activating GNAS Mutations and Outcomes with Chemotherapy in Metastatic Appendiceal Adenocarcinoma. Ann Surg Oncol. 2026 Apr; 33(4):3453-3461.
-
Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2026 02 01; 12(2):149-158.
-
Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (Alliance). J Natl Cancer Inst. 2025 Dec 01; 117(12):2643-2652.
-
Mutation and Microsatellite Instability (MSI) Affect the Differential Gene Expression of Folic Acid and 5-Flourouracil Metabolism-Related Genes in Colorectal Carcinoma. Curr Oncol. 2025 Nov 26; 32(12).
-
Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance). Eur J Cancer. 2025 Sep 09; 227:115694.